Literature DB >> 24832845

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.

Michael D Mandel, Mandel D Michael1, Anita Bálint, Barbara D Lovász, László Gulácsi, Bálint Strbák, Petra A Golovics, Klaudia Farkas, Zsuzsanna Kürti, Blanka K Szilágyi, Anna Mohás, Tamás Molnár, Péter L Lakatos.   

Abstract

BACKGROUND AND AIMS: To assess work disability (WD) rates in an inflammatory bowel disease (IBD) cohort involving patients with Crohn's disease (CD) or ulcerative colitis (UC) cohort and to identify possible clinical or demographic factors associated with WD. To our knowledge, this is the first study from Eastern Europe that has estimated indirect costs in IBD.
METHODS: Data from 443 (M/F: 202/241, CD/UC: 260/183, mean age: 35.5 (CD) and 40.5 (UC) years, biological drug exposure 31.2/11.5%) consecutive patients were included. WD data were collected by questionnaire and the work productivity and activity impairment instrument. Disability pension (DP) rates in the general population were retrieved from public databases.
RESULTS: The overall DP rate in this IBD population was 32.3%, with partial disability in 24.2%. Of all DP events, 88.8% were directly related to IBD. Overall, full DP was more prevalent in IBD (RR: 1.51, p < 0.001) and CD (RR: 1.74, p < 0.001) but not in UC compared to the general population and also in CD compared to UC (OR 1.57, p = 0.03). RR for full DP was increased only in young CD patients (RR<35 year olds: 9.4; RR36-40 year olds: 9.4 and 5.6, p < 0.01 for both). In CD, age group, previous surgery, disease duration, frequent relapses, and the presence of arthritis/arthralgia were associated with an increased risk for DP. Among employed patients, absenteeism and presenteeism was reported in of 25.9 and 60.3% patients, respectively, leading to a 28% loss of work productivity and a 32% activity loss, and was associated with disease activity and age group. Average cost of productivity loss due to disability and sick leave with a human capital approach was 1,450 and 430 €/patient/year in IBD, respectively (total productivity loss 1,880 €/patient/year), the costs of presenteeism were 2,605 (SD = 2,770) and 2,410 (SD = 2,970) €/patient/year in CD and UC, respectively.
CONCLUSION: Risk of DP was highly increased in young CD patients (sixfold to ninefold). Previous surgery and presence of arthritis/arthralgia was identified as risk factors for DP. Work productivity is significantly impaired in IBD and is associated with high productivity loss.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24832845     DOI: 10.1007/s10198-014-0603-7

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  31 in total

Review 1.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  The validity and reproducibility of a work productivity and activity impairment instrument.

Authors:  M C Reilly; A S Zbrozek; E M Dukes
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

3.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

4.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

5.  European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis.

Authors:  E F Stange; S P L Travis; S Vermeire; C Beglinger; L Kupcinkas; K Geboes; A Barakauskiene; V Villanacci; A Von Herbay; B F Warren; C Gasche; H Tilg; Stefan W Schreiber; J Schölmerich; W Reinisch
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 6.  Quantifying the economic burden of productivity loss in rheumatoid arthritis.

Authors:  Ivana Filipovic; David Walker; Fiona Forster; Alistair S Curry
Journal:  Rheumatology (Oxford)       Date:  2011-01-18       Impact factor: 7.580

7.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

Review 8.  Productivity costs in economic evaluations: past, present, future.

Authors:  Marieke Krol; Werner Brouwer; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

9.  Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease.

Authors:  Henrik Stjernman; Curt Tysk; Sven Almer; Magnus Ström; Henrik Hjortswang
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-08       Impact factor: 2.566

10.  Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study.

Authors:  Uwe Siebert; Johannes Wurm; Raffaella Matteucci Gothe; Marjan Arvandi; Stephan R Vavricka; Roland von Känel; Stefan Begré; Michael C Sulz; Christa Meyenberger; Markus Sagmeister
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

View more
  22 in total

1.  Wage subsidies and hiring chances for the disabled: some causal evidence.

Authors:  Stijn Baert
Journal:  Eur J Health Econ       Date:  2014-12-12

Review 2.  Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.

Authors:  Fanni Rencz; Márta Péntek; Martin Bortlik; Edyta Zagorowicz; Tibor Hlavaty; Andrzej Śliwczyński; Mihai M Diculescu; Limas Kupcinskas; Krisztina B Gecse; László Gulácsi; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

3.  The socio-economic impact of work disability due to inflammatory bowel disease in Brazil.

Authors:  Renata de S B Fróes; Ana Teresa Pugas Carvalho; Antonio Jose de V Carneiro; Adriana Maria Hilu de Barros Moreira; Jessica P L Moreira; Ronir R Luiz; Heitor S de Souza
Journal:  Eur J Health Econ       Date:  2017-05-18

Review 4.  Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.

Authors:  Jamison Pike; Scott D Grosse
Journal:  Appl Health Econ Health Policy       Date:  2018-12       Impact factor: 2.561

Review 5.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

6.  Comparison of Employer Productivity Metrics to Lost Productivity Estimated by Commonly Used Questionnaires.

Authors:  Bethany T Gardner; Ann Marie Dale; Skye Buckner-Petty; Linda Van Dillen; Benjamin C Amick; Bradley Evanoff
Journal:  J Occup Environ Med       Date:  2016-02       Impact factor: 2.162

7.  Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists.

Authors:  Erdem Suticen; Nuh Atas; Aslihan Avanoglu Guler; Orhun Akdogan; Hakan Babaoğlu; Hasan Satis; Hazan Karadeniz; Seminur Haznedaroglu; Mehmet Akif Ozturk; Abdurrahman Tufan
Journal:  Clin Rheumatol       Date:  2021-02-01       Impact factor: 2.980

8.  Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland.

Authors:  Przemysław Holko; Paweł Kawalec; Małgorzata Mossakowska; Andrzej Pilc
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

9.  Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease.

Authors:  Lieke M Spekhorst; Bas Oldenburg; Ad A van Bodegraven; Dirk J de Jong; Floris Imhann; Andrea E van der Meulen-de Jong; Marieke J Pierik; Janneke C van der Woude; Gerard Dijkstra; Geert D'Haens; Mark Löwenberg; Rinse K Weersma; Eleonora A M Festen
Journal:  World J Gastroenterol       Date:  2017-12-14       Impact factor: 5.742

10.  Women's Earnings are more Affected by Inflammatory Bowel Disease than Men's: A Register-Based Swedish Cohort Study.

Authors:  Åsa H Everhov; Gustaf Bruze; Jonas Söderling; Johan Askling; Jonas Halfvarson; Karin Westberg; Petter Malmborg; Caroline Nordenvall; Jonas F Ludvigsson; Ola Olén
Journal:  J Crohns Colitis       Date:  2021-06-22       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.